Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
07/2003
07/31/2003WO2003061660A1 Melanocortin receptor agonists
07/31/2003WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators
07/31/2003WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
07/31/2003WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
07/31/2003WO2003047516A3 Pyrimidine compounds
07/31/2003WO2003039460A3 Mitotic kinesin inhibitors
07/31/2003WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
07/31/2003WO2002092065A3 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
07/31/2003WO2002062762A3 Potassium channel openers
07/31/2003WO2002060892A8 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
07/31/2003WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
07/31/2003WO2002040471A9 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
07/31/2003US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their
07/31/2003US20030144520 Inhibit p38- alpha kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein noninterfering substituent;
07/31/2003US20030144517 Chiral fluoroquinolone arginine salt forms
07/31/2003US20030144510 Preparation of pharmaceutical salts
07/31/2003US20030144507 Sulfonamide-containing heterocyclic compounds
07/31/2003US20030144506 Formula 1 are useful in treating abnormal cell growth in mammals by administering pharmaceutical compositions.
07/31/2003US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4
07/31/2003US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists
07/31/2003US20030144325 For reducing levels of tumor necrosis factor alpha in mammals; for example, 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafuoroisoindoline
07/31/2003US20030144323 Phenylalkynes
07/31/2003US20030144320 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders
07/31/2003US20030144311 Propanoic acid derivatives as intergrin receptor antagonists
07/31/2003US20030144309 Inhibitors of Src and other protein kinases
07/31/2003US20030144308 Fructose 1,6-bisphosphatase inhibitors
07/31/2003US20030144306 A liquid oral composition comprising a proton pump inhibitor, e,g, omeprazole, lansoprazole,and a buffer; can also contain a parietal cell activator; acid resistance; side effect reduction; kits; drug delivery; Zollinger-Ellison syndrome
07/31/2003US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents
07/31/2003US20030144302 Process for making substituted pyrazoles
07/31/2003US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
07/31/2003US20030144299 Method of treating depression with delta receptor agonist compounds
07/31/2003US20030144297 Substituted aryl 1,4-pyrazine derivatives
07/31/2003US20030144290 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives
07/31/2003US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis
07/31/2003US20030144282 Inhibitors of cytosolic phospholipase A2
07/31/2003US20030144281 Substituted benzimidazole compounds
07/31/2003US20030144279 5-Heterocyclo-pyrazoles
07/31/2003US20030144278 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
07/31/2003US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same
07/31/2003US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis
07/31/2003US20030144273 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
07/31/2003US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents
07/31/2003US20030144267 Novel compounds
07/31/2003US20030144262 Heteroaryl and heterocyclic nitrogen ring containing hydrazide compounds useful for treating neurodegenerative disorderes
07/31/2003US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases
07/31/2003US20030144251 Pesticidal 1-arylpyrazoles
07/31/2003US20030144175 Protease inhibitors
07/31/2003US20030143235 For angiogenesis treatment and destruction of new angiogenic vasculature; useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury; therapy of rheumatoid arthritis
07/31/2003CA2473796A1 Substituted quinazolin-4-ylamine analogues
07/31/2003CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors
07/31/2003CA2473036A1 Melanocortin receptor agonists
07/31/2003CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators
07/31/2003CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
07/31/2003CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
07/30/2003EP1330453A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents
07/30/2003EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases
07/30/2003EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
07/30/2003EP1330443A1 Substituted phenyluracils
07/30/2003EP1330442A1 Phthalazinone derivatives
07/30/2003EP1330436A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists
07/30/2003EP1330292A2 Radioactive member for use in brachytherapy and method of making
07/30/2003EP1123287B1 Insecticidal 3- (substituted pyridyl) -1, 2, 4-triazoles
07/30/2003EP0964684B1 Crystalline pharmaceutical product
07/30/2003EP0946541B1 Quinolines and their therapeutic use
07/30/2003EP0835252B1 Triazole antifungal agents
07/30/2003CN1433411A Chemical compounds
07/30/2003CN1433405A Quinazoline compounds
07/30/2003CN1433402A Cycloamine CCR5 receptor antagonists
07/30/2003CN1433396A Pharmaceutical compounds
07/30/2003CN1432569A Prepn process of pyrazole derivative
07/30/2003CN1116295C Cycloalkylaminomethylpyrrolidine derivatives
07/30/2003CN1116039C Molecular dispersion composition with enhanced bioavailability
07/29/2003US6600589 Electrochromic device with a yellow filter
07/29/2003US6600037 4,5-disubstituted-2-aminopyrimidines
07/29/2003US6599963 Polymer substrate, and a synergistic mixture of a hindered amine and a phosphorus or bromine compound.
07/29/2003US6599926 Anticoagulant agents for treatment and prevention of thromboembolic disorders
07/29/2003US6599924 2-hetaryl-3,4 dihydro-2H-pyrrole pesticide
07/29/2003US6599910 Substituted triazole compounds
07/29/2003US6599908 Fused polycyclic 2-aminopyrimidine derivatives
07/29/2003US6599902 For treating or preventing a protein kinase related disorder
07/29/2003CA2124584C Tetrahydropyridine derivative and cardiotonic agent containing the same as effective component
07/29/2003CA2082777C (quinolin-2-ylmethoxy) indole/cyclodextrin complex
07/29/2003CA2066332C Substituted 3-(pyridinylamino)-indoles and benzo¬b|thiophenes, a process for their preparation and their use as medicaments
07/24/2003WO2003060475A2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
07/24/2003WO2003059905A1 Pyrrolidone carboxamides
07/24/2003WO2003059903A2 Substituted 4-aminopyridine derivatives used as pest control agents
07/24/2003WO2003059894A1 Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
07/24/2003WO2003059893A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
07/24/2003WO2003059892A1 Substituted alkyl uracils and the use thereof
07/24/2003WO2003059891A1 Substituted pyridazinones as inhibitors of p38
07/24/2003WO2003059884A1 Modulators of lxr
07/24/2003WO2003059883A1 (4-oxopiperidin-1-yl)benzoic acid derivatives and process for their preparation
07/24/2003WO2003059873A1 Potassium channel modulators
07/24/2003WO2003059807A2 Crystalline solids of carvedilol and processes for their preparation
07/24/2003WO2003059393A1 Pantoprazole cyclodextrin inclusion complexes
07/24/2003WO2003059355A1 Quinazolinone compounds in combined modalities for improved cancer treatment
07/24/2003WO2003059353A1 Tyrosyl derivatives and their use as p2x7 receptor modulators
07/24/2003WO2003059351A1 Hydroxylated indole derivatives and uses thereof
07/24/2003WO2003059348A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
07/24/2003WO2003059341A1 1,3-disubstituted and 1,3,3,-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
1 ... 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 ... 1080